Axial symptoms predict mortality in patients with Parkinson disease and subthalamic stimulation
Authors:
- Brian LauBLBrian Lau
- Niklaus MeierNMNiklaus Meier
- Giulia SerraGSGiulia Serra
- Virginie CzerneckiVCVirginie Czernecki
- Michael SchuepbachMSMichael Schuepbach
- Soledad NavarroSNSoledad Navarro
- Philippe CornuPCPhilippe Cornu
- David GrabliDGDavid Grabli
- Yves AgidYAYves Agid
- Marie VidailhetMVMarie Vidailhet
- Carine KarachiCKCarine Karachi
- Marie-Laure WelterMWMarie-Laure Welter
Open Access
- 28 May 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (22) , e2559-e2570
Abstract
Objective To characterize how disease progression is associated with mortality in a large cohort of patients with Parkinson disease (PD) with long-term follow-up after subthalamic nucleus deep brain stimulation (STN-DBS). Methods Motor and cognitive disabilities were assessed before and 1, 2, 5, and 10 years after STN-DBS in 143 consecutive patients with PD. We measured motor symptoms “off” and “on” levodopa and STN-DBS and recorded causes of death. We used linear mixed models to characterize symptom progression, including interactions between treatment conditions and time to determine how treatments changed efficacy. We used joint models to link symptom progression to mortality. Results Median observation time was 12 years after surgery, during which akinesia, rigidity, and axial symptoms worsened, with mean increases of 8.8 (SD 6.5), 1.8 (3.1), and 5.4 (4.1) points from year 1–10 after surgery (“on” dopamine/“on” STN-DBS), respectively. Responses to dopaminergic medication and STN-DBS were attenuated with time, but remained effective for all except axial symptoms, for which both treatments and their combination were predicted to be ineffective 20 years after surgery. Cognitive status significantly declined. Forty-one patients died, with a median time to death of 9 years after surgery. The current level of axial disability was the only symptom that significantly predicted death (hazard ratio 4.30 [SE 1.50] per unit of square-root transformed axial score). Conclusions We quantified long-term symptom progression and attenuation of dopaminergic medication and STN-DBS treatment efficacy in patients with PD and linked symptom progression to mortality. Axial disability significantly predicts individual risk of death after surgery, which may be useful for planning therapeutic strategies in PD.Keywords
This publication has 46 references indexed in Scilit:
- Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset?Journal of Neurology, Neurosurgery & Psychiatry, 2011
- What predicts mortality in Parkinson disease?Neurology, 2010
- Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implantsBrain, 2010
- Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson diseaseJournal of Clinical Investigation, 2010
- Relationships between age and late progression of Parkinson's disease: a clinico-pathological studyBrain, 2010
- The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 yearsMovement Disorders, 2008
- Patterns of levodopa response in Parkinson's disease: a clinico-pathological studyBrain, 2007
- Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeysBrain, 2007
- Young‐ versus older‐onset Parkinson's disease: Impact of disease and psychosocial consequencesMovement Disorders, 2003
- Unified Parkinson's disease rating scale characteristics and structureMovement Disorders, 1994